



AGENDA

** Mountain Standard Time **

THURSDAY, January 6, 2022

18:00 – 20:00 **Networking Reception**

FRIDAY, January 7, 2022

6:45 – 7:30 **Breakfast**

7:30 – 8:00 **The Year 2021 in Review**

*Presenter: Michael Charlton, MBBS, FRCP
University of Chicago
Illinois, USA*

SESSION 1: ONE-STOP SHOP

*Moderators: Rohit Loomba, MD, MHSc, University of California San Diego (La Jolla, California, USA)
Maru Rinella, MD, Northwestern University Feinberg School of Medicine (Chicago, Illinois, USA)*

8:00 – 8:20 **FXR: Clinical Trial Summary of FXR Agonists**

*Presenter: Stephen Harrison, MD
University of Oxford
San Antonio, Texas, USA*

8:20 – 8:30 **Open Mic Discussion**

8:30 – 8:50 **FGF-19: Aldafermin Trial Results and Tribulations**

*Presenter: Vincent Wong, MD
The Chinese University of Hong Kong
Shatin, Hong Kong*

8:50 – 9:00 **Open Mic Discussion**

9:00 – 9:20 **FGF-21: Cover to Cover FGF-21 Trials**

*Presenter: Rohit Loomba, MD, MHSc
University of California San Diego
La Jolla, California, USA*

9:20 – 9:30 **Open Mic Discussion**

9:30 – 9:50 **Break – Exhibit Hall/Poster Viewing**



AGENDA

SESSION 2: LATEST CLINICAL TRIAL RESULTS

Moderators: **Vlad Ratziu, MD**, *Hôpital Pitié Salpêtrière, Institute of Cardiometabolism, and Nutrition and University of Paris (Paris, France)*
Stephen Harrison, MD, *University of Oxford (San Antonio, Texas, USA)*

- 9:50 – 10:15 **Key Congress Presentations**
Presenter: Vincent Wong, MD
The Chinese University of Hong Kong
Shatin, Hong Kong
- 10:15 – 10:25 **One Oral Presentation (Distinguished Abstract #29)**
- 10:25 – 10:40 **Q&A**

SESSION 3: BACK TO THE BIOLOGIC BASIS OF NASH PROGRESSION

Moderators: **Brent Tetri, MD**, *Saint Louis University School of Medicine (St. Louis, Missouri, USA)*
Frank A. Anania, MD, *Deputy Director, Division of Hepatology, U.S. Food and Drug Administration (Silver Spring, Maryland)*

- 10:40 – 10:55 **Role of Phage Therapies in Liver Disease**
Presenter: Bernd Schnabl, MD
University of California San Diego
La Jolla, California, USA
- 10:55 – 11:10 **Emerging Data on Lipotoxicity in NASH**
Presenter: Harmeet Malhi, MBBS
Mayo Clinic
Rochester, Minnesota, USA
- 11:10 – 11:25 **Why Is NASH-Related HCC Resistant to Treatment?**
Presenter: Mathias Heikenwälder, MD
German Cancer Research Center
Heidelberg, Germany
- 11:25 – 11:40 **Organoids in NASH Therapeutics**
Presenter: David Brenner, MD
University of California San Diego
La Jolla, California, USA
- 11:40 – 12:00 **Panel Discussion**
- 12:00 – 16:00 **Interactive Dialogue on NASH Topics**



AGENDA

FRIDAY, January 7, 2022

CME Lunch Symposium: 12:30 – 13:45

Register: <https://www.chronicliverdisease.org/NASHTAG-SYMP22/>

Pearls and Pitfalls: Update on Emerging Therapies in NASH

Supported by an educational grant from Novo Nordisk Inc. and Merck & Co., Inc.

*Faculty: Michael Charlton, MBBS, FRCP
University of Chicago
Chicago, Illinois, USA*

*Rohit Loomba, MD, MHSc
University of California San Diego
La Jolla, California, USA*

SESSION 4: WHAT'S HAPPENING IN MAJOR CONSORTIA ACROSS THE FIELD?

Moderators: Arun Sanyal, MD, Virginia Commonwealth University Health System (Richmond, Virginia, USA)

Quentin M. Anstee, MD, FRCP, Newcastle University (Newcastle upon Tyne, United Kingdom)

Manal Abdelmalek, MD, Duke University (Durham, North Carolina, USA)

16:00 – 16:20

NIMBLE Update

*Presenter: Arun Sanyal, MD
Virginia Commonwealth University Health System
Richmond, Virginia, USA*

16:20 – 16:40

LITMUS Update

*Presenter: Quentin M. Anstee, MD, FRCP
Newcastle University
Newcastle upon Tyne, United Kingdom*

16:40 – 17:00

Two Oral Presentations (Distinguished Abstracts #8 and 12)

17:00 – 17:20

Cirrhosis Network Update

*Presenter: Vijay Shah, MD
Mayo Clinic
Rochester, Minnesota, USA*

17:20 – 17:40

Panel Discussion

17:40 – 18:00

Break – Exhibit Hall/Poster Viewing



AGENDA

SESSION 5: ARTIFICIAL INTELLIGENCE PLATFORMS IN NASH TRIALS

Moderators: *Naim Alkhouri, MD, Arizona Liver Health (Glendale, Arizona, USA)*
Kenneth Cusi, MD, University of Florida (Gainesville, Florida, USA)

18:00 – 18:15

New Data on Path AI

Presenter: *Mazen Nouredin, MD*
Cedars-Sinai Medical Center
Los Angeles, California, USA

18:15 – 18:30

New Data on HistoIndex

Presenter: *Naim Alkhouri, MD*
Arizona Liver Health
Glendale, Arizona, USA

18:30 – 18:45

What's Next in AI Platforms in NASH Trials and Future

Presenter: *Arun Sanyal, MD*
Virginia Commonwealth University Health System
Richmond Virginia, USA

18:45 – 19:00

Panel Discussion

Stephen Harrison, MD, University of Oxford (San Antonio, Texas, USA)
Quentin M. Anstee, MD, FRCP, Newcastle University (Newcastle upon Tyne, United Kingdom)
Dave Kleiner, MD, Center for Cancer Research - National Cancer Institute (Bethesda, Maryland, USA)
Katy Wack, PhD, Vice President, Clinical and Regulatory Affairs, PathAI (Boston, Massachusetts, USA)
Gideon Ho, Co-founder and Chief Commercial Officer, HistoIndex (Launchpad, Singapore)

SATURDAY, January 8, 2022

6:45 – 7:30

Breakfast

SESSION 6: WHAT'S NEW OUT THERE, AND HOW TO INTERPRET WHAT IT ALL MEANS

Moderators: *Vlad Ratziu, MD, Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition, and University of Paris (Paris, France)*
Stephen Harrison, MD, University of Oxford (San Antonio, Texas, USA)
Brent A. Tetri, MD, Saint Louis University School of Medicine (St. Louis, Missouri, USA)

7:30 – 7:50

Update from the AASLD NASH Task Force

Presenter: *Maru Rinella, MD*
Northwestern University Feinberg School of Medicine
Chicago, Illinois, USA

7:50 – 8:10

New Data on Wet Biomarkers

Presenter: *Philip Newsome, MD*
Institute of Biomedical Research - The Medical School, University of Birmingham
Birmingham, United Kingdom

8:10 – 8:30

Two Oral Presentations (Distinguished Abstracts #1 and 16)



AGENDA

- 8:30 – 8:50** **Combination Therapy Data in 2022: Current Status**
Presenter: Michael Charlton, MBBS, FRCP
University of Chicago
Chicago, Illinois, USA
- 8:50 – 9:10** **New Data on Predicting Treatment Response by Imaging**
Presenter: Rohit Loomba, MD, MHSc
University of California San Diego
La Jolla, California, USA
- 9:10 – 9:40** **Panel Discussion**
Vlad Ratziu, MD, Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition, and University of Paris (Paris, France)
Stephen Harrison, MD, University of Oxford (San Antonio, Texas, USA)
Amy Articulo, DO, FACOG, FACOOG, Dipl ABOM, Medical Director, NASH, Novo Nordisk, Inc. (Plainsboro, New Jersey, USA)
- 9:40 – 10:00** **Break – Exhibit Hall/Poster Viewing**

SESSION 7: NOVEL TARGETS

Moderators: Naga P. Chalasani, MD, Indiana University School of Medicine (Indianapolis, Indiana, USA)
Celeste Thomas, MD, University of Chicago (Chicago, Illinois, USA)
Philip Newsome, MBBS, The Medical School, University of Birmingham (Birmingham, United Kingdom)

- 10:00 – 10:15** **PNPLA3 Knockdown as Treatment of NASH**
Presenter: Luca Valenti, MD
Università degli Studi Milano
Milane, Italy
- 10:15 – 10:30** **HSD17B13 Knockdown and Inhibition as Treatment of NASH**
Presenter: Yaron Rotman, MD
NIH Intramural Research Program
Bethesda, Maryland, USA
- 10:30 – 10:50** **Two Oral Presentations (Distinguished Abstracts #13 and 28)**
- 10:50 – 11:05** **Uncouplers in the Treatment of NASH**
Presenter: Gerald I. Shulman, MD
Yale University School of Medicine
New Haven, Connecticut, USA
- 11:05 – 11:20** **Targeting the Gut-Liver Axis in NAFLD Using CARBALIVE**
Presenter: Rajiv Jalan, MD
University of London
London, United Kingdom
- 11:20 – 11:35** **Mechanisms of VLDL Turnover: Implications in NASH Therapeutics**
Presenter: David E. Cohen, MD, PhD
Harvard Medical School
Boston, Massachusetts, USA
- 11:35 – 12:00** **Panel Discussion**



AGENDA

12:00 – 16:00

A la Carte Roundtable Discussion Related to Drug Development

SATURDAY, January 8, 2022

CME Lunch Symposium: 12:30 – 13:30

Register: <https://www.chronicliverdisease.org/NASHsymposium-Nashtag/>

New Advances in NASH Diagnostics and Prognostics

Supported by an educational grant from Siemens Healthcare Diagnostics, Inc.

Faculty: Mazen Nouredin, MD, MHSc
Cedars-Sinai Medical Center
Los Angeles, California, USA

SESSION 8: BASIC SCIENCE

Moderators: David Brenner, MD, University of California San Diego (La Jolla, California, USA)
Vijay Shah, MD, Mayo Clinic (Rochester, Minnesota, USA)

16:00 – 16:20

Two Oral Presentations (Distinguished Abstracts #3 and 32)

16:20 – 16:35

Single Cell Transcriptomics and NASH

Presenter: Prakash Ramachandran, MD
University of Edinburgh
Edinburgh, United Kingdom

16:35 – 16:50

Inflammation and Gut Dysbiosis

Presenter: Michael Karin, MD
University of California San Diego
La Jolla, California, USA

16:50 – 17:05

Integrins and Fibrosis

Presenter: Scott Turner, PhD, Senior Vice President, Research
Pliant Therapeutics
San Francisco, California, USA

17:05 – 17:20

Addressing Unmet Needs in NASH Fibrosis

Presenter: Scott L. Friedman, MD
Icahn School of Medicine at Mount Sinai
New York, New York, USA

17:20 – 17:40

Overview of Dual/Triple Agonists

Presenter: Samuel Klein, MD
Washington University School of Medicine
St. Louis, Missouri, USA

17:40 – 18:00

Break – Exhibit Hall/Poster Viewing



AGENDA

SESSION 9: NASH ENDPOINTS AND REGULATORY LANDSCAPE

Moderators: *Vlad Ratziu, MD, Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition, and University of Paris (Paris, France)*
Erin Quirk, MD, President and Chief Medical Officer, Terns Pharmaceuticals, Inc. (Foster City, California, USA)

18:00 – 18:10

Lessons Learned from Early Pioneers in NASH Drug Development

Presenter: *David Shapiro, MD, FRCP*
Integrated Quality Resources
San Diego, California, USA

18:10 – 18:30

Non-cirrhotic Trial Endpoints-Is It Time to Pivot?

Presenter: *Stephen Harrison, MD*
University of Oxford
San Antonio, Texas, USA

18:30 – 19:00

Fireside Chat

Stephen Rossi, PharmD, Chief Development Officer, NorthSea Therapeutics (Amsterdam, The Netherlands)
Erin Quirk, MD, President and Chief Medical Officer, Terns Pharmaceuticals, Inc. (Foster City, California, USA)
Robert Myers, MD, Vice President, Client Development, Gilead Sciences, Inc. (Foster City, California, USA)
Katy Wack PhD, Vice President, Clinical and Regulatory Affairs, PathAI (Boston, Massachusetts, USA)
Gideon Ho, Co-founder and Chief Commercial Officer, HistoIndex (Launchpad, Singapore)
Steven Berman, MPH, U.S. Food and Drug Administration (Silver Spring, Maryland, USA)
Joseph Toerner, MD, U.S. Food and Drug Administration (Silver Spring, Maryland, USA)
Vlad Ratziu, MD, Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition, and University of Paris (Paris, France)
Rohit Loomba, MD, MHSc, University of California San Diego (La Jolla, California, USA)
Stephen Harrison, MD, University of Oxford (San Antonio, Texas, USA)

19:00 – 19:15

Cirrhotic Trial Endpoints-Are We Ready for NITs?

Presenter: *Vlad Ratziu, MD*
Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition, and University of Paris
Paris, France

19:15 – 19:40

Fireside Chat

Stephen Rossi, PharmD, Chief Development Officer, NorthSea Therapeutics (Amsterdam, The Netherlands)
Erin Quirk, MD, President and Chief Medical Officer, Terns Pharmaceuticals, Inc. (Foster City, California, USA)
Robert Myers, MD, Vice President, Client Development, Gilead Sciences, Inc. (Foster City, California, USA)
Katy Wack PhD, Vice President, Clinical and Regulatory Affairs, PathAI (Boston, Massachusetts, USA)
Gideon Ho, Co-founder and Chief Commercial Officer, HistoIndex (Launchpad, Singapore)
Steven Berman, MPH, U.S. Food and Drug Administration (Silver Spring, Maryland, USA)
Joseph Toerner, MD, U.S. Food and Drug Administration (Silver Spring, Maryland, USA)
Vlad Ratziu, MD, Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition, and University of Paris (Paris, France)
Rohit Loomba, MD, MHSc, University of California San Diego (La Jolla, California, USA)
Stephen Harrison, MD, University of Oxford (San Antonio, Texas, USA)

19:40 – 19:45

NASH-TAG 2022 Recap and Future

Presenter: *Stephen Harrison, MD*
University of Oxford
San Antonio, Texas, USA

19:45

Meeting Adjourn